Table 3.
Toxicity profile of afatinib, gefitinib, and erlotinib
| Toxicity | Grade 1-2 |
Grade 3-4 |
||||
|---|---|---|---|---|---|---|
| Afatinib | Gefitinib | Erlotinib | Afatinib | Gefitinib | Erlotinib | |
| Total | 116 (70.3) | 164 (71.3) | 53 (73.6) | 12 (7.3) | 6 (2.6) | 3 (1.8) |
| Rash and acne | 76 (46.1) | 131 (57.0) | 47 (65.3) | 3 (1.8) | 1 (1.4) | 3 (1.8) |
| Stomatitis | 50 (30.3) | 31 (13.5) | 8 (11.1) | 0 | 0 | 0 |
| Paronychia | 44 (26.7) | 21 (9.1) | 13 (18.1) | 4 (2.4) | 0 | 0 |
| Diarrhea | 32 (19.4) | 33 (14.3) | 13 (18.2) | 6 (3.0) | 0 | 0 |
| Dry skin | 18 (10.9) | 45 (19.6) | 12 (16.7) | 0 | 1 (1.4) | 0 |
| Pruritus | 17 (10.3) | 79 (34.3) | 21 (29.2) | 0 | 0 | 0 |
| Anorexia | 7 (4.2) | 15 (6.5) | 7 (9.7) | 1 (0.6) | 1 (1.4) | 0 |
| Nausea/Vomiting | 0 | 4 (1.7) | 1 (1.4) | 0 | 0 | 0 |
| Fatigue | 1 (0.6) | 3 (1.3) | 1 (1.5) | 1 (0.6) | 0 | 0 |
| Alopecia | 0 | 15 (6.5) | 2 (2.8) | 0 | 1 (1.4) | 0 |
| Interstitial lung disease | 0 | 0 | 0 | 1 (0.6) | 0 | 0 |
| Increased AST/ALT | 0 | 2 (0.9) | 0 | 0 | 2 (2.8) | 0 |
Values are presented as number (%). ALT, alanine aminotransferase; AST, aspartate aminotransferase.